We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.23B
AUM Growth
-$160M
Cap. Flow
-$204M
Cap. Flow %
-3.9%
Top 10 Hldgs %
34.65%
Holding
139
New
8
Increased
26
Reduced
20
Closed
24

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$97.9M
2
UNH icon
UnitedHealth
UNH
+$60M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$51.5M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$37.9M
5
THC icon
Tenet Healthcare
THC
+$26.7M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$108M
2
ARGX icon
argenx
ARGX
+$94.8M
3
ABBV icon
AbbVie
ABBV
+$80.5M
4
PFE icon
Pfizer
PFE
+$57.8M
5
GH icon
Guardant Health
GH
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.41%
2 Miscellaneous 1.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMMB
76
Chemomab Therapeutics
CMMB
$18M
$8.25M 0.16%
644,544
– –
SRRK icon
77
Scholar Rock
SRRK
$6.31B
$7.95M 0.15%
879,003
+211,060
+32% +$1.69M
MREO
78
Mereo BioPharma
MREO
$44.7M
$7.95M 0.15%
10,605,522
– –
IVVD icon
79
Invivyd
IVVD
$263M
$7.91M 0.15%
5,270,400
– –
IMA
80
ImageneBio Inc
IMA
$57.7M
$7.8M 0.15%
244,495
– –
CGEM icon
81
Cullinan Oncology
CGEM
$1.31B
$6.72M 0.13%
637,287
– –
VSTM icon
82
Verastem
VSTM
$680M
$6.64M 0.13%
1,375,270
-58,063
-4% -$285K
XBI icon
83
State Street SPDR S&P Biotech ETF
XBI
$10.6B
$6.34M 0.12%
76,400
– –
FOLD
84
DELISTED
Amicus Therapeutics
FOLD
$6.3M 0.12%
+516,000
New +$5.81M
ARGX icon
85
argenx
ARGX
$62B
$6.14M 0.12%
16,200
-253,500
-94% -$94.8M
NPCE icon
86
Neuropace
NPCE
$482M
$5.98M 0.11%
4,012,281
– –
CRVS icon
87
Corvus Pharmaceuticals
CRVS
$1.1B
$5.9M 0.11%
6,943,654
– –
XFOR icon
88
X4 Pharmaceuticals
XFOR
$347M
$5.78M 0.11%
193,924
+26,363
+16% +$1.25M
VIGL
89
DELISTED
Vigil Neuroscience
VIGL
$5.61M 0.11%
448,891
+37,700
+9% +$463K
BNTX icon
90
BioNTech
BNTX
$24.8B
$5.45M 0.1%
+36,300
New +$5.59M
SNY icon
91
CALL
Sanofi
SNY
$104B
$4.84M 0.09%
+100,000
New +$4.39M
DMRA
92
Damora Therapeutics
DMRA
$1.73B
$4.7M 0.09%
163,637
– –
SYBX
93
DELISTED
Synlogic
SYBX
$4.58M 0.09%
402,000
– –
NXTC icon
94
NextCure
NXTC
$30.4M
$3.82M 0.07%
225,918
– –
AMRX icon
95
Amneal Pharmaceuticals
AMRX
$6B
$3.15M 0.06%
1,583,490
– –
AFIB
96
DELISTED
Acutus Medical Inc
AFIB
$3.05M 0.06%
2,648,386
– –
BCAB
97
DELISTED
BIOATLA INC
BCAB
$2.74M 0.05%
+6,647
New +$2.76M
APLT
98
DELISTED
Applied Therapeutics
APLT
$2.32M 0.04%
3,050,921
-1,199,079
-28% -$948K
TARA icon
99
Protara Therapeutics
TARA
$231M
$2.23M 0.04%
830,641
– –
CALC icon
100
CalciMedica
CALC
$13.7M
$2.08M 0.04%
59,476
– –
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2022 Portfolio in Review

As of Q4 2022, OrbiMed held 139 positions worth $5.23B, down 3% from $5.39B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed withdrew a net $204M in Q4 2022, closing 24 positions and reducing 20 holdings. Its most notable exit was Tricida, Inc. Common Stock, an estimated $108M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $19.5M.

  • OrbiMed's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 171,000 shares worth $19.5M.
  • OrbiMed added most to Disc Medicine in Q4 2022, an estimated $97.9M increase.
  • OrbiMed's biggest Q4 2022 reduction was argenx, cutting an estimated $94.8M.
  • OrbiMed fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $108M.
  • OrbiMed's ten largest holdings make up 35% of its $5.23B portfolio in Q4 2022.
  • OrbiMed opened 8 new positions and closed 24 in Q4 2022.
  • OrbiMed's portfolio value fell 3% quarter-over-quarter to $5.23B.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.